“Programmed cell death” sounds a bit sinister, but it’s actually a normal and healthy process.
Browsing: cancer
Biomoda’s CyPath diagnostic assay is based on molecular marker technology originally developed at the Los Alamos National Laboratory.
NuVue Therapeutics is commercializing a site-specific regimen of cancer therapy for soft tissue tumors.
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
Keryx Biopharmaceuticals, Inc. is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.
CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced, treatment-resistant soft tissue sarcoma.
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis in a $477 million deal.